SinoMab BioScience Limited (3681.HK)

SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong. Its product pipeline comprises SM03 (Suciraslimab), a first-in-class anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA); is in phase II clinical trial to treat non-Hodgkin's lymphoma and systemic lupus erythematosus; and is in phase I clinical trial to treat alzheimer's disease and sjogren's syndrome. It also develops SM17, a humanized anti-IL-25 receptor, which is in phase I clinical trial to treat asthma and atopic dermatitis, as well as to treat idiopathic pulmonary fibrosis; and SN1011, a Bruton's tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, neuromyelitis optical spectrum disorder, and multiple sclerosis, as well as to treat systemic lupus erythematosus. In addition, the company is developing SM06, a humanised Anti-CD22, that is in preclinical trial to treat systemic lupus erythematosus, rheumatoid arthritis, neuromyelitis optica spectrum disorder, and sjogren's syndrome; and SM09, a humanised Anti-CD22, which is in preclinical trial to treat non-hodgkin's lymphoma and autoimmune diseases. Further, it develops Anti-CGC antibody, which is in preclinical trial to treat vitiligo and alopecia areata; and Bispecific antibody candidate (bsAb), which is in preclinical trial to treat osteoporosis. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Tai Po, Hong Kong.